65,437 trials
Hypertension
Primary: Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 Weeks — -25.34; -17.94; -19.81 mmHg
Acromegaly
Primary: Change in Growth Hormone (GH) Level From Screening to End of Study (Week 24) — -1.7; -2.1 µg/L
Diabetes Mellitus
Primary: Saxagliptin Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) — 99.45; 105.28 ng*hr/mL
Pain
Primary: Use Days With One or More Misuse Occasions — 2112; 294 days
Diabetic Peripheral Neuropathy · Neuralgia
Primary: Placebo vs. Active Comparison of the Change From Average Pain at Baseline to Average Pain at 4 Weeks. — 1.64; 2.12 units on a scale — p=0.083
Metabolic Syndrome
Primary: Change in Total Cholesterol (TC), High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C) and Triglycerides (TG) Levels From Baseline…
Pulmonary Disease, Chronic Obstructive
Primary: First Occurrence of (Moderate or Severe) COPD Exacerbation — 1277; 1414 number of first occurrences — p=<0.0001
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants
Gastrointestinal Stromal Tumors
Primary: Progression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008) — 109.0; 111.0 days
Attention Deficit Hyperactivity Disorder
Primary: The Number of Chromosomal Aberrations Per 100 Cells Excluding Gaps at Baseline and at the End of Treatment i.e Day 84 (Week 12) — 1.05; 0.75; 0.53; 0.41 number of…
Coronary Artery Disease
Primary: Target Lesion Failure — 8.2; 8.3 percentage of participants
Multiple Sclerosis
Primary: Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study — 0.203; 0.161; 0.331 Estimate relapses per year
Type 2 Diabetes Mellitus (T2DM)
Primary: Change From Baseline in Glucose 5-Hour Incremental AUC at Week 6 — -83.9; 27.0 mg*hr/dL — p=<0.001
Depressive Disorder, Major Depressive Disorder
Primary: Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs) — 13; 15; 1; 0 participants
Retinal Disease
Primary: Change in Visual Acuity at Month 3 Compared to Baseline. — 0 ETDRS letters